Positive Phase 2 Data for the Duchenne Agent SRP-5051 MOMENTUM Study Announced.

Published Date: 01 Feb 2024

Compared to previously approved eteplirsen, Sarepta's first treatment for Duchenne muscular dystrophy, the investigational agent showed a significantly greater increase in dystrophin expression and exon skipping over the course of a 28-week treatment period.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot